 Pfizer Inc. PFE, -4.12 said Monday that it will help develop and commercialize sisunatovir, LianBios LIAN, 7.14 experimental respiratory syncytial virus RSV treatment candidate, in mainland China, Hong Kong, Macau and Singapore. Sisunatovir is being tested as a treatment for pediatric and adult patients. 